Earlier this year, the UK government announced the Rare Diseases Framework, outlining strategy to improve the delivery of care to the 3.5 million people living within the four nations of the UK with a rare disorder.
All eyes were on pharma biotech companies in 2020, as they raced against each other to find solutions to alleviate the Covid-19 pandemic through vaccines and treatments.
We discuss how payers will adapt to the ATMPs Revolution ,effecting the pricing and reimbursement framework.
Some initial market access decisions, made during a unique healthcare crisis, hint at lasting changes for pharmaceutical market access.
Inbeeo dives into the data from our COVID-19 Impact on Market Access Activities Dashboard and identifies three positive trends that emerged.
What are ATMPs, and why the buzz? Inbeeo hosted a webinar addressing their market impact, focusing on US and EU challenges with 60+ participants in the Q&A.
France’s healthcare industry strategic council CSIS met an agreement with the French Government to strengthen France’s appeal for HealthCare industries. Inbeeo dives in to investigate the impact on market access and pricing.
The Health Foundation and ICHOM are among the many stakeholders calling for an evolution of how we look at value in healthcare. Here are four trends emerging from their pledge.
Five tips worth keeping mind when planning for market access. An infographic.
I have learned the hard way that defining the value of a pharmaceutical innovation is not as easy as “Bob’s your uncle”.
